243 related articles for article (PubMed ID: 28450700)
1. Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
Van Woensel M; Mathivet T; Wauthoz N; Rosière R; Garg AD; Agostinis P; Mathieu V; Kiss R; Lefranc F; Boon L; Belmans J; Van Gool SW; Gerhardt H; Amighi K; De Vleeschouwer S
Sci Rep; 2017 Apr; 7(1):1217. PubMed ID: 28450700
[TBL] [Abstract][Full Text] [Related]
2. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
[TBL] [Abstract][Full Text] [Related]
3. Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: in vivo evaluation.
Danhier F; Messaoudi K; Lemaire L; Benoit JP; Lagarce F
Int J Pharm; 2015 Mar; 481(1-2):154-61. PubMed ID: 25644286
[TBL] [Abstract][Full Text] [Related]
4. T7 peptide-decorated exosome-based nanocarrier system for delivery of Galectin-9 siRNA to stimulate macrophage repolarization in glioblastoma.
Li C; Guan N; Liu F
J Neurooncol; 2023 Mar; 162(1):93-108. PubMed ID: 36854924
[TBL] [Abstract][Full Text] [Related]
5. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme.
Kadiyala P; Li D; Nuñez FM; Altshuler D; Doherty R; Kuai R; Yu M; Kamran N; Edwards M; Moon JJ; Lowenstein PR; Castro MG; Schwendeman A
ACS Nano; 2019 Feb; 13(2):1365-1384. PubMed ID: 30721028
[TBL] [Abstract][Full Text] [Related]
6. Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses.
Le Mercier M; Mathieu V; Haibe-Kains B; Bontempi G; Mijatovic T; Decaestecker C; Kiss R; Lefranc F
J Neuropathol Exp Neurol; 2008 May; 67(5):456-69. PubMed ID: 18431251
[TBL] [Abstract][Full Text] [Related]
7. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
8. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
9. Endogenous Galectin-1 in T Lymphocytes Regulates Anti-prostate Cancer Immunity.
Corapi E; Carrizo G; Compagno D; Laderach D
Front Immunol; 2018; 9():2190. PubMed ID: 30319642
[TBL] [Abstract][Full Text] [Related]
10. A simple self-assembly nanomicelle based on brain tumor-targeting peptide-mediated siRNA delivery for glioma immunotherapy via intranasal administration.
Tang L; Zhang R; Wang Y; Zhang X; Yang Y; Zhao B; Yang L
Acta Biomater; 2023 Jan; 155():521-537. PubMed ID: 36384220
[TBL] [Abstract][Full Text] [Related]
11. A Trojan-Horse-Like Biomimetic Nano-NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo-Immunotherapy.
Zhang L; Zhang Y; Wang X; Zhou Y; Qi J; Gu L; Zhao Q; Yu R; Zhou X
Small; 2023 Nov; 19(44):e2301439. PubMed ID: 37420326
[TBL] [Abstract][Full Text] [Related]
12. CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice.
Jadidi-Niaragh F; Atyabi F; Rastegari A; Kheshtchin N; Arab S; Hassannia H; Ajami M; Mirsanei Z; Habibi S; Masoumi F; Noorbakhsh F; Shokri F; Hadjati J
J Control Release; 2017 Jan; 246():46-59. PubMed ID: 27993599
[TBL] [Abstract][Full Text] [Related]
13. Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses.
Liu N; Yang X; Gao C; Wang J; Zeng Y; Zhang L; Yin Q; Zhang T; Zhou H; Li K; Du J; Zhou S; Zhao X; Zhu H; Yang Z; Liu Z
J Nucl Med; 2024 May; 65(5):728-734. PubMed ID: 38514084
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulatory silica nanoparticle boosts innate immunity in brain tumors.
Bielecki PA; Lorkowski ME; Becicka WM; Atukorale PU; Moon TJ; Zhang Y; Wiese M; Covarrubias G; Ravichandran S; Karathanasis E
Nanoscale Horiz; 2021 Feb; 6(2):156-167. PubMed ID: 33400743
[TBL] [Abstract][Full Text] [Related]
15. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
16. KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells.
Zheng Y; Zhang H; Xiao C; Deng Z; Fan T; Zheng B; Li C; He J
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586772
[TBL] [Abstract][Full Text] [Related]
17. Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma.
Medikonda R; Choi J; Pant A; Saleh L; Routkevitch D; Tong L; Belcaid Z; Kim YH; Jackson CM; Jackson C; Mathios D; Xia Y; Shah PP; Patel K; Kim T; Srivastava S; Huq S; Ehresman J; Pennington Z; Tyler B; Brem H; Lim M
J Neurosurg; 2022 Feb; 136(2):379-388. PubMed ID: 34388730
[TBL] [Abstract][Full Text] [Related]
18. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker.
Martínez-Bosch N; Vilariño N; Alameda F; Mojal S; Arumí-Uria M; Carrato C; Aldecoa I; Ribalta T; Vidal N; Bellosillo B; Menéndez S; Del Barco S; Gallego O; Pineda E; López-Martos R; Hernández A; Mesia C; Esteve-Codina A; de la Iglesia N; Balañá C; Martínez-García M; Navarro P
Cells; 2023 Mar; 12(6):. PubMed ID: 36980184
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
20. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
